Form 4: Cue Biopharma CEO Granted 1.875M Stock Options
Insider Transaction Report
Cue Biopharma's CEO, Azam Usman, was granted 1.875 million stock options with an exercise price of $0.72, vesting over 48 months.
Summary
- Azam Usman, Chief Executive Officer and Director of Cue Biopharma, Inc. (CUE), was granted 1,875,000 stock options.
- The stock options have an exercise price of $0.72 per share.
- The earliest transaction date for this grant was September 29, 2025.
- The options will become exercisable in 48 monthly installments, commencing on September 29, 2026.
- The expiration date for these stock options is September 28, 2035.
- The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 7
Explanation: The grant of a significant number of stock options to the CEO is generally viewed positively as it enhances management's alignment with long-term shareholder interests and signals confidence in the company's future prospects.
Positives
- The grant of 1,875,000 stock options to the CEO aligns management's long-term interests with shareholder value.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged and structured approach to insider transactions.
Future Outlook
The vesting schedule extending to September 2026 and the option expiration in September 2035 suggest a long-term incentive structure for the CEO, aligning his financial interests with the company's sustained performance over the next decade.
Industry Context
This grant is a standard practice in the biotechnology industry to incentivize and retain key executives, aligning their compensation with the long-term success and growth of the company, particularly given the extended development cycles common in biopharma.
Comparison to Industry Standards
- The grant of stock options to a CEO is a common compensation practice across the biotechnology and broader public company landscape, aiming to align executive incentives with shareholder returns.
- The vesting schedule over 48 months is typical for executive equity grants, promoting long-term retention and performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up pre-scheduled trades to avoid accusations of trading on material non-public information. | 09/29/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for future transactions under the plan, reflecting good corporate governance practices. |
Stakeholder Impact
- Shareholders: The grant aligns the CEO's financial incentives with long-term shareholder value creation, potentially leading to improved company performance. However, future exercise of options could lead to dilution.
- Employees: May signal stability and confidence in leadership, potentially boosting morale.
Next Steps
- The stock options will begin vesting in 48 monthly installments starting September 29, 2026.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Date of earliest transaction (stock option grant date). |
| 09/29/2026 | Start date for the 48 monthly vesting installments of the stock options. |
| 09/28/2035 | Expiration date of the granted stock options. |
Keywords
Cue Biopharma, CUE, Azam Usman, Stock Options, CEO, Insider Transaction, Form 4, Equity Grant, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.